Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S.

For the last installment of the America in Focus project this year, we spoke with 14 Americans from all walks of life who are ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Eli Lilly’s orforglipron pill helps maintain weight loss after Zepbound or Wegovy injections, with FDA review underway. Learn ...